- Home
- GXO vs MIRM Comparison
GXO vs MIRM Comparison
Compare GXO & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | GXO | MIRM |
|---|---|---|
| Founded | 2021 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.2B | 7.2B |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | GXO | MIRM |
|---|---|---|
| Price | $47.67 | $97.80 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 11 | 13 |
| Target Price | $67.91 | ★ $119.85 |
| AVG Volume (30 Days) | ★ 1.6M | 649.6K |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 74.59 |
| EPS | ★ 0.25 | N/A |
| Revenue | ★ $13,178,000,000.00 | $19,138,000.00 |
| Revenue This Year | $6.81 | $26.22 |
| Revenue Next Year | $5.95 | $22.04 |
| P/E Ratio | $191.92 | ★ N/A |
| Revenue Growth | ★ 12.55 | N/A |
| 52 Week Low | $45.00 | $63.23 |
| 52 Week High | $66.85 | $130.00 |
Technical Indicators
Market Signals| Indicator | GXO | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 46.98 | 40.55 |
| Support Level | $45.52 | $88.08 |
| Resistance Level | $48.94 | $98.03 |
| Average True Range (ATR) | 1.25 | 3.30 |
| MACD | 0.17 | 0.33 |
| Stochastic Oscillator | 71.32 | 24.02 |
Price Performance
Historical ComparisonAbout GXO GXO Logistics Inc.
GXO Logistics Inc is a contract logistics company. Its revenue is diversified across numerous verticals and customers, including many multinational corporations. It provides warehousing and distribution, order fulfillment, e-commerce, reverse logistics, and other supply chain services differentiated by its ability to deliver technology-enabled, customized solutions at scale. Geographically, it generates revenue from the United Kingdom, the United States, the Netherlands, France, Spain, Italy, and other countries, and derives the majority of its revenue from the United Kingdom.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.